• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗病毒治疗下的乙肝病毒动力学揭示了乙肝e抗原阳性和阴性感染的差异。

Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.

作者信息

Ribeiro Ruy M, Germanidis Georgios, Powers Kimberly A, Pellegrin Bertrand, Nikolaidis Paul, Perelson Alan S, Pawlotsky Jean-Michel

机构信息

Los Alamos National Laboratory, Los Alamos, New Mexico, USA.

出版信息

J Infect Dis. 2010 Nov 1;202(9):1309-18. doi: 10.1086/656528.

DOI:10.1086/656528
PMID:20874517
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3058754/
Abstract

BACKGROUND

Hepatitis B e antigen (HBeAg)–negative chronic hepatitis B infection has a presentation and clinical course that is divergent from that of HBeAg‐positive infection. The former usually presents with lower viral levels but faster progression to liver disease. We sought to better understand the balance between replication and the immune response against hepatitis B virus (HBV).

METHODS

Viral kinetics in 50 HBeAg‐negative patients under various treatment protocols with interferon α and/or nucleoside or nucleotide analogs was analyzed. HBV DNA level was measured frequently and the data fitted to a viral dynamic model. A meta‐analysis of all published studies of viral kinetics in HBeAg‐positive and HBeAg‐negative infection was also conducted.

RESULTS

We found that the clearance of both HBV virions and infected cells was significantly faster in HBeAg‐negative infection than in HBeAg‐positive infection. In HBeAg‐negative infection, there was also a negative correlation between baseline HBV DNA levels and infected cell half‐life, suggesting that the higher the viral load the faster the turnover of infected cells.

CONCLUSIONS

These results reveal the dual role played by the immune response in maintaining lower viral levels and inducing faster turnover of infected cells, the latter of which may be responsible for the more aggressive nature of HBeAg‐negative infection.

摘要

背景

乙肝e抗原(HBeAg)阴性的慢性乙型肝炎感染的表现和临床病程与HBeAg阳性感染不同。前者通常病毒水平较低,但肝病进展较快。我们试图更好地理解乙肝病毒(HBV)复制与免疫反应之间的平衡。

方法

分析了50例HBeAg阴性患者在使用干扰素α和/或核苷或核苷酸类似物的各种治疗方案下的病毒动力学。频繁测量HBV DNA水平,并将数据拟合到病毒动力学模型。还对所有已发表的关于HBeAg阳性和HBeAg阴性感染的病毒动力学研究进行了荟萃分析。

结果

我们发现,HBeAg阴性感染中HBV病毒颗粒和受感染细胞的清除明显快于HBeAg阳性感染。在HBeAg阴性感染中,基线HBV DNA水平与受感染细胞半衰期之间也存在负相关,这表明病毒载量越高,受感染细胞的更新速度越快。

结论

这些结果揭示了免疫反应在维持较低病毒水平和诱导受感染细胞更快更新方面所起的双重作用,后者可能是HBeAg阴性感染更具侵袭性的原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d704/3058754/cf51fc81d8a5/nihms226228f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d704/3058754/b6ab95b6b039/nihms226228f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d704/3058754/8681a9e4324d/nihms226228f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d704/3058754/706e633537d8/nihms226228f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d704/3058754/cf51fc81d8a5/nihms226228f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d704/3058754/b6ab95b6b039/nihms226228f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d704/3058754/8681a9e4324d/nihms226228f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d704/3058754/706e633537d8/nihms226228f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d704/3058754/cf51fc81d8a5/nihms226228f4.jpg

相似文献

1
Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.抗病毒治疗下的乙肝病毒动力学揭示了乙肝e抗原阳性和阴性感染的差异。
J Infect Dis. 2010 Nov 1;202(9):1309-18. doi: 10.1086/656528.
2
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.富马酸替诺福韦二吡呋酯对乙型肝炎 e 抗原阳性、丙氨酸氨基转移酶正常和乙型肝炎病毒 DNA 水平较高患者的影响。
Gastroenterology. 2014 May;146(5):1240-8. doi: 10.1053/j.gastro.2014.01.044. Epub 2014 Jan 23.
3
[A cohort study on the epidemiological characteristics of HBeAg sero-clearance in HBeAg positive chronic hepatitis B patients in Jiangsu province from 2012 to 2014].
Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Feb 10;38(2):179-184. doi: 10.3760/cma.j.issn.0254-6450.2017.02.009.
4
Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).对既往接受聚乙二醇化干扰素α2a(40kDa;派罗欣)抗病毒治疗失败的慢性乙型肝炎患者的治疗。
Antivir Ther. 2008;13(4):555-62.
5
Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.IL28B 附近的多态性与 HBeAg 阳性慢性乙型肝炎患者对聚乙二醇干扰素的血清学应答。
Gastroenterology. 2012 Mar;142(3):513-520.e1. doi: 10.1053/j.gastro.2011.11.025. Epub 2011 Nov 19.
6
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.宿主和病毒因素对接受聚乙二醇化干扰素-α-2a治疗的乙肝e抗原阳性慢性乙型肝炎患者的影响。
Antivir Ther. 2011;16(5):629-37. doi: 10.3851/IMP1841.
7
Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.聚乙二醇化干扰素α治疗经治慢性乙型肝炎患者。
PLoS One. 2015 Apr 2;10(4):e0122259. doi: 10.1371/journal.pone.0122259. eCollection 2015.
8
Early hepatitis B viral DNA clearance predicts treatment response at week 96.早期乙型肝炎病毒 DNA 清除可预测第 96 周的治疗应答。
World J Gastroenterol. 2017 Apr 28;23(16):2978-2986. doi: 10.3748/wjg.v23.i16.2978.
9
Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.恩替卡韦治疗的慢性乙型肝炎患者病毒学应答与FIB-4指数的关系
World J Gastroenterol. 2015 Nov 21;21(43):12421-9. doi: 10.3748/wjg.v21.i43.12421.
10
Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.接受核苷/核苷酸类似物治疗的乙肝e抗原阴性慢性乙型肝炎患者严重再激活时的血清乙肝表面抗原动力学
Antivir Ther. 2013;18(8):979-86. doi: 10.3851/IMP2615. Epub 2013 Jun 6.

引用本文的文献

1
A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B.一种用于治疗慢性乙型肝炎的衣壳组装调节剂作用的多尺度模型。
PLoS Comput Biol. 2025 May 6;21(5):e1012322. doi: 10.1371/journal.pcbi.1012322. eCollection 2025 May.
2
Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers.联合血清替代标志物预测乙型肝炎患者cccDNA动态变化
PLoS Comput Biol. 2025 Jan 9;21(1):e1012615. doi: 10.1371/journal.pcbi.1012615. eCollection 2025 Jan.
3
Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design.

本文引用的文献

1
Hepatitis B virus clearance rate estimates.乙型肝炎病毒清除率估计值。
Hepatology. 2009 May;49(5):1779-80; author reply 1780-1. doi: 10.1002/hep.22874.
2
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.人类免疫缺陷病毒1型与乙型肝炎病毒合并感染个体中乙型肝炎病毒DNA的病毒动力学:拉米夫定、替诺福韦或联合治疗的相似疗效
Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754.
3
A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection.
新型衣壳组装调节剂GST-HG141在慢性乙型肝炎患者中的安全性、药代动力学及抗病毒疗效:一项随机、安慰剂对照的1期试验
Virol J. 2024 Dec 20;21(1):328. doi: 10.1186/s12985-024-02584-8.
4
Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.聚乙二醇干扰素对接受布列韦肽治疗的丁型肝炎病毒感染患者病毒动力学的影响。
JHEP Rep. 2024 Mar 24;6(8):101070. doi: 10.1016/j.jhepr.2024.101070. eCollection 2024 Aug.
5
Chronic hepatitis B virus infection in Eastern Ethiopia: Clinical characteristics and determinants of cirrhosis.埃塞俄比亚东部慢性乙型肝炎病毒感染:肝硬化的临床特征及决定因素
World J Hepatol. 2024 Jul 27;16(7):995-1008. doi: 10.4254/wjh.v16.i7.995.
6
A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis B.一种用于治疗慢性乙型肝炎的衣壳组装调节剂作用的多尺度模型。
bioRxiv. 2024 Jul 16:2024.07.16.603658. doi: 10.1101/2024.07.16.603658.
7
Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics.丙型肝炎病毒动力学数学模型的数据参数估计与学习进展。
Mathematics (Basel). 2022 Jun 2;10(12). doi: 10.3390/math10122136. Epub 2022 Jun 19.
8
Imaging of Hepatitis B Virus Nucleic Acids: Current Advances and Challenges.乙型肝炎病毒核酸的影像学研究:现状与挑战
Viruses. 2022 Mar 8;14(3):557. doi: 10.3390/v14030557.
9
Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials.丁型肝炎病毒 (HDV):临床试验中的研究治疗药物。
Expert Opin Investig Drugs. 2022 Sep;31(9):905-920. doi: 10.1080/13543784.2021.1977795. Epub 2021 Oct 1.
10
Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric Mice.了解乙型肝炎病毒动力学和人源化嵌合小鼠中干扰素α治疗的抗病毒作用。
J Virol. 2021 Jun 24;95(14):e0049220. doi: 10.1128/JVI.00492-20.
一种解释慢性乙型肝炎病毒感染期间戊型肝炎抗原阴性突变体选择的机制。
J Virol. 2009 Feb;83(3):1379-92. doi: 10.1128/JVI.01902-08. Epub 2008 Nov 12.
4
Treatment predictors of a sustained virologic response in hepatitis B and C.乙型和丙型肝炎病毒持续病毒学应答的治疗预测因素
J Hepatol. 2008 Oct;49(4):634-51. doi: 10.1016/j.jhep.2008.07.013. Epub 2008 Jul 31.
5
Virion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia.慢性乙型肝炎感染中病毒体的半衰期与病毒血症水平密切相关。
Hepatology. 2008 Oct;48(4):1079-86. doi: 10.1002/hep.22469.
6
Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.肝内乙型肝炎病毒产生能力受损导致大多数HBeAg阴性患者病毒血症水平较低。
Gastroenterology. 2007 Sep;133(3):843-52. doi: 10.1053/j.gastro.2007.06.057. Epub 2007 Jul 3.
7
Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B.慢性乙型肝炎抗病毒治疗期间早期病毒动力学对T细胞反应性的影响
Antivir Ther. 2007;12(5):705-18.
8
Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.乙肝e抗原阴性慢性乙型肝炎患者的治疗模式
Expert Opin Investig Drugs. 2007 Jun;16(6):777-86. doi: 10.1517/13543784.16.6.777.
9
Management of hepatitis B: summary of a clinical research workshop.乙型肝炎的管理:临床研究研讨会总结
Hepatology. 2007 Apr;45(4):1056-75. doi: 10.1002/hep.21627.
10
The half-life of hepatitis B virions.乙肝病毒颗粒的半衰期。
Hepatology. 2006 Nov;44(5):1117-21. doi: 10.1002/hep.21364.